Trial Search Results

Brief Behavioral Intervention for Insomnia During Chemotherapy


To evaluate the efficacy of the Brief Behavioral Therapy for Insomnia (BBT-I) in treating insomnia among breast cancer patients receiving chemotherapy.


- To evaluate the efficacy of the BBT-I in treating cancer-related symptoms such as cancer-related fatigue and cognitive difficulties in breast cancer patients receiving chemotherapy.

- To examine potential moderators and mediators of BBT-I intervention effects on insomnia, cognitive difficulties, and fatigue. In particular, we are interested in age, depression and anxiety and side effects (hot flashes) as potential moderators of the intervention effects as well as evaluating modifiable behavioral and physiological mechanisms as hypothesized mediators

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):


  • Behavioral: Brief Behavioral Therapy for Insomnia (BBT-I)
  • Behavioral: Healthy Eating Education Learning (HEAL)





   - Female

   - Diagnosis of Breast Cancer (Stage I-IIIA)

   - Scheduled for planned cancer treatment (eg, chemotherapy or biologic agents), or
   treatment is continuing

   - Has ≥ 6 weeks of cancer treatment (eg, chemotherapy or biologic agents) remaining

   - ≥ 21 years of age.

   - Able to understand written and spoken English.

   - Sleep disturbance of 8 or greater on the ISI, and insomnia that began or got worse
   with diagnosis of cancer or treatment with chemotherapy (to exclude pre-existing,
   chronic insomnia).

   - Karnofsky score ≥ 70


   - Have an unstable self-reported medical or psychiatric illness (Axis I - current or
   within the last 5 years).

   - Be currently pregnant or nursing

   - History of substance abuse or meet criteria for current alcohol abuse or dependence

   - History (self-reported) of sleep apnea or restless leg syndrome (RLS)

   - Self-report or have a medical record of an unstable comorbid medical or psychiatric
   condition that would make it unsafe or impossible to adhere to the study protocol

   - Unable or unwilling to discontinue anxiolytics within 4 hours of education sessions

   - Irregular heartbeat or arrhythmia (self-reported or in the medical record)

Ages Eligible for Study

21 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Oxana Palesh